About this episode

Susan Levinson discusses the potential of recombinant human plasma gelsolin as a treatment for inflammation-related conditions.

Plasma gelsolin is an abundant, endogenous regulator of inflammation that is consumed during severe inflammatory insults. When levels fall too low, patients are at higher risk of organ damage and death, particularly in settings like acute respiratory distress syndrome where a dysregulated inflammatory response floods the lungs with fluid and leaves patients dependent on ventilatory support with no approved therapies today. BioAegis Therapeutics is working to turn recombinant human plasma gelsolin into a pipeline-in-a-product. Susan Levinson, CEO of BioAegis, discusses recombinant human plasma gelsolin as a potential first-in-class treatment for ARDS and other inflammasome-driven conditions, how it modulates cytokine storms without suppressing the immune system, and its potential in other conditions including neurodegenerative diseases.

People in this episode

Guest: Susan Levinson

Topics covered

• inflammation
• health
• biotechnology
• therapeutics
• cytokine storms
• neurodegenerative diseases

Keywords

• plasma gelsolin
• inflammation
• ARDS
• cytokine storms
• biotechnology
• therapeutics
• neurodegenerative diseases

Mentioned in this episode

Organizations: BioAegis Therapeutics

Products: recombinant human plasma gelsolin

Places: acute respiratory distress syndrome

More episodes of The Bio Report

• Addressing a Data Problem to Enable AI-Drug Discovery · July 15, 2026 · 41 min
• Turning Multi Specific Antibody Design into an Engineering Discipline with AI · July 8, 2026 · 30 min
• Addressing the Treatment Gap in Ischemic Stroke · July 1, 2026 · 30 min
• Building a Genetics Engine to Crack the Target Bottleneck · June 17, 2026 · 53 min

Explore listener stats, chart rankings, contacts and more on the The Bio Report podcast page.